Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/53285| Title: | First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis. | Authors: | Toscano S.;Spelman T.;Ozakbas S.;Alroughani R.;Chisari C.G.;Lo Fermo S.;Prat A.;Girard M.;Duquette P.;Izquierdo G.;Eichau S.;Grammond P.;Boz C.;Kalincik T.;Blanco Y.;Buzzard K.;Skibina O.;Sa M.J.;van der Walt A.;Butzkueven H.;Terzi M.;Gerlach O.;Grand'Maison F.;Foschi M.;Surcinelli A.;Barnett M.;Lugaresi A.;Onofrj M.;Yamout B.;Khoury S.J.;Prevost J.;Lechner-Scott J.;Maimone D.;Amato M.P.;Spitaleri D.;Van Pesch V.;Macdonell R.;Cartechini E.;de Gans K.;Slee M.;Castillo-Trivino T.;Soysal A.;Sanchez-Menoyo J.L.;Laureys G.;Van Hijfte L.;McCombe P.;Altintas A.;Weinstock-Guttman B.;Aguera-Morales E.;Etemadifar M.;Ramo-Tello C.;John N.;Turkoglu R.;Hodgkinson S.;Besora S.;Van Wijmeersch B.;Fernandez-Bolanos R.;Patti F. | Monash Health Department(s): | Neurology | Institution: | (Toscano) Department of Biomedical and Biotechnological Sciences, University of Catania, Via Santa Sofia 78, Catania, Italy (Toscano, Chisari, Lo Fermo, Patti) Multiple Sclerosis Unit, University-Hospital G. Rodolico - San Marco, Catania, Italy (Spelman) MSBase Foundation, Melbourne, VIC, Australia (Spelman) Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden (Ozakbas) Dokuz Eylul University, Konak, Izmir, Turkey (Alroughani) Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait (Chisari, Lo Fermo, Patti) Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania, Italy (Prat, Girard, Duquette) CHUM MS Center and Universite de Montreal, Montreal, Canada (Izquierdo, Eichau) Hospital Universitario Virgen Macarena, Sevilla, Spain (Grammond) CISSS Chaudiere-Appalache, Levis, Canada (Boz) KTU Medical Faculty Farabi Hospital, Trabzon, Turkey (Kalincik) CORe, Department of Medicine, The University of Melbourne, Melbourne, Australia (Kalincik) Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia (Blanco) Center of Neuroimmunology, Service of Neurology, Hospital Clinic de Barcelona, Barcelona, Spain (Buzzard, Skibina) Department of Neurology, Box Hill Hospital, Melbourne, Australia (Sa) Department of Neurology, Centro Hospitalar Universitario de Sao Joao, Porto, Portugal (Sa) Faculty of Health Sciences, University Fernando Pessoa, Porto, Portugal (van der Walt, Butzkueven) Department of Neurology, The Alfred Hospital, Melbourne, Australia (Terzi) Medical Faculty, 19 Mayis University, Samsun, Turkey (Gerlach) Academic MS Center Zuyd, Department of Neurology, Zuyderland Medical Center, Sittard-Geleen, Netherlands (Gerlach) School for Mental Health and Neuroscience, Department of Neurology, Maastricht University Medical Center, Maastricht, Netherlands (Grand'Maison) Neuro Rive-Sud, Quebec, Canada (Foschi, Surcinelli) Department of Neuroscience, Multiple Sclerosis Center, Neurology Unit, S. Maria delle Croci Hospital, AUSL Romagna, Ravenna, Italy (Foschi) Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy (Barnett) Brain and Mind Centre, Sydney, Australia (Lugaresi) IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy (Lugaresi) Department of Biomedical and Neuromotor Science, University of Bologna, Bologna, Italy (Onofrj) Department of Neuroscience, Imaging, and Clinical Sciences, University G. D'Annunzio, Chieti, Italy (Yamout, Khoury) Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon (Prevost) CSSS Saint-Jerome, Saint-Jerome, Canada (Lechner-Scott) School of Medicine and Public Health, University Newcastle, Newcastle, Australia (Maimone) Centro Sclerosi Multipla, Garibaldi Hospital, Catania, Italy (Amato) Department NEUROFARBA, University of Florence, Florence, Italy (Amato) IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy (Spitaleri) Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy (Van Pesch) Department of Neurology, Cliniques Universitaires Saint-Luc, Universite Catholique de Louvain (UCLouvain), Brussels, Belgium (Macdonell) Austin Health, Melbourne, Australia (Cartechini) AST 3 Macerata, Marche, Italy (de Gans) Department of Neurology, Groene Hart Ziekenhuis, Zuid-Holland, Gouda, Netherlands (Slee) Flinders University, Adelaide, Australia (Castillo-Trivino) Hospital Universitario Donostia and IIS Biodonostia, San Sebastian, Spain (Soysal) Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey (Sanchez-Menoyo) Department of Neurology, Galdakao-Usansolo University Hospital, Osakidetza-Basque Health Service, Biocruces, Spain (Laureys, Van Hijfte) Department of Neurology, Ghent Universitary Hospital, Ghent, Belgium (McCombe) Royal Brisbane and Women's Hospital, University of Queensland, Brisbane, Australia (Altintas) Department of Neurology, School of Medicine, Koc University, Koc University Research Center for Translational Medicine (KUTTAM), Istanbul, Turkey (Weinstock-Guttman) Department of Neurology, Buffalo General Medical Center, Buffalo, United States (Aguera-Morales) University Hospital Reina Sofia, Cordoba, Spain (Etemadifar) Department of Neurosurgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran, Islamic Republic of (Ramo-Tello) Hospital Germans Trias i Pujol, Badalona, Spain (John) Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Australia (John) Department of Neurology, Monash Health, Clayton, Australia (Turkoglu) Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey (Hodgkinson) Liverpool Hospital, Sydney, Australia (Besora) Hospital Universitari Mutua de Terrassa, Barcelona, Spain (Van Wijmeersch) Universitair MS Centrum, Hasselt University, Hasselt-Pelt, Belgium (Van Wijmeersch) Rehabilitation & MS Centre, Pelt, Belgium (Fernandez-Bolanos) Department of Neurology, Hospital Universitario Virgen de Valme, Spain |
Issue Date: | 20-Feb-2025 | Copyright year: | 2025 | Publisher: | Elsevier B.V. | Place of publication: | Switzerland | Publication information: | Neurotherapeutics. (no pagination), 2025. Article Number: e00552. Date of Publication: 2025. | Journal: | Neurotherapeutics | Abstract: | Predicting long-term prognosis and choosing the appropriate therapeutic approach in patients with Multiple Sclerosis (MS) at the time of diagnosis is crucial in view of a personalized medicine. We investigated the impact of early therapeutic response on the 5-year prognosis of patients with relapsing-remitting MS (RRMS). We recruited patients from MSBase Registry covering the period between 1996 and 2022. All patients were diagnosed with RRMS and actively followed-up for at least 5 years to explore the following outcomes: clinical relapses, confirmed disability worsening (CDW) and improvement (CDI), EDSS 3.0, EDSS 6.0, conversion to secondary progressive MS (SPMS), new MRI lesions, Progression Independent of Relapse Activity (PIRA). Predictors included demographic, clinical and radiological data, and sub-optimal response (SR) within the first year of treatment. Female sex (HR 1.27; 95 % CI 1.16-1.40) and EDSS at baseline (HR 1.19; 95 % CI 1.15-1.24) were independent risk factors for the occurrence of relapses during the first 5 years after diagnosis, while high-efficacy treatment (HR 0.78; 95 % CI 0.67-0.91) and age at diagnosis (HR 0.83; 95 % CI 0.79-0.86) significantly reduced the risk. SR predicted clinical relapses (HR = 3.84; 95 % CI 3.51-4.19), CDW (HR = 1.74; 95 % CI 1.56-1.93), EDSS 3.0 (HR = 3.01; 95 % CI 2.58-3.51), EDSS 6.0 (HR = 1.77; 95 % CI 1.43-2.20) and new brain (HR = 2.33; 95 % CI 2.04-2.66) and spinal (HR 1.65; 95 % CI 1.29-2.09) MRI lesions. This study highlights the importance of selecting the appropriate DMT for each patient soon after MS diagnosis, also providing clinicians with a practical tool able to calculate personalized risk estimates for different outcomes.Copyright © 2025 The Authors | DOI: | http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1016/j.neurot.2025.e00552 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/53285 | Type: | Article In Press | Subjects: | multiple sclerosis nuclear magnetic resonance imaging progressive multiple sclerosis relapsing remitting multiple sclerosis |
Type of Clinical Study or Trial: | Observational study (cohort, case-control, cross sectional, or survey) Qualitative study |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.